Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Mechlorethamine gel for mycosis fungoides in cutaneous T-cell lymphoma	Mechlorethamine (Ledaga; Valchlor)	Cutaneous T-cell lymphoma (CTCL)	Haematological Cancer and Lymphomas	2019	View \| Download
Migalastat for Fabry disease in children aged 12 to 15 years	Migalastat hydrochloride (Galafold; AT1001)	Fabry disease	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2019	View \| Download
MTX-110 for newly-diagnosed diffuse intrinsic pontine glioma	Panobinostat (MTX-110; Farydak; LBH589; LBH-589; panobinostat lactate anhydrous)	Glioma	Neurological Cancer	2019	View \| Download
Nerinetide for acute ischaemic stroke	Nerinetide (NA-1)	Ischaemic stroke	Cardiovascular System	2019	View \| Download
Nintedanib for progressive fibrosing interstitial lung disease	Nintedanib (Vargatef; Ofev; nintedanib esilate)	Progressive fibrosing interstitial lung disease (PF-ILD)	Respiratory System	2019	View \| Download
Niraparib for advanced ovarian, fallopian tube or primary peritoneal cancer - maintenance therapy	Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Nitisinone for Alkaptonuria	Nitisinone (Orfadin; SYN118)	Alkaptonuria	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2019	View \| Download
Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3)	Melanoma	Skin Cancer	2019	View \| Download
Nivolumab for high risk invasive urothelial carcinoma - adjuvant	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Urothelial cancer	Urological Cancer	2019	View \| Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastro-oesophageal junction cancer , Oesophageal cancer	Gastrointestinal Cancer , Head and Neck Cancer	2019	View \| Download